Wide discrepancies in activated clotting times measured by two devices were detected for a patient with lupus anticoagulant in a cardiac surgery

Abstract

Introduction:

For a patient with lupus anticoagulant (LA), activated coagulation time (ACT) was measured with two different types of devices (HEMOCHRON^® 801 and HEMOCHRON^® Jr).

Case Report:

ACTs during heparinization measured with the HEMOCHRON^® 801 were over the range of measurement, while those with the HEMOCHRON^® Jr. reflected an almost normal response to heparin.

Discussion:

The phospholipid contained in an activating agent of the HEMOCHRON^® Jr was suggested to have counteracted the effect of LA.

Conclusion:

It was indicated that the coagulation status for LA-positive patients might be better assessed by ACT measured with phospholipid in an activating agent, although careful interpretation is required.

Keywords

activated clotting time cardiac surgery lupus anticoagulant phospholipid antiphospholipid syndrome

Get full access to this article

View all access options for this article.

References

Levine

Branch

Rauch

. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752–763.

Gorki

Malinovski

Stanbridge

. The antiphospholipid syndrome and heart valve surgery. Eur J Cardiothorac Surg 2008; 33: 168–181.

Aylsworth

Stefan

Woitas

. New technology, old standards: disparate activated clotting time measurements by the Hemochron Jr compared with the standard Hemochron. Ann Thorac Surg 2004; 77: 973–976.

Pan

Jobes

Riper

. Modified microsample ACT test for heparin monitoring. J Extra Corpor Technol 1996; 28: 16–20.

Accriva Diagnostics, Inc. Package Insert for HEMOCHRON^® Jr. ACT+. San Diego, CA.